CEP-32496 CEP32496 Agerafenib RXDX-105 RXDX105 CAS: 1188910-76-0

CAS NO: 1188910-76-0
CEP-32496 CEP32496 Agerafenib RXDX-105 RXDX105
Chemical Name: CEP-32496 (free base)
Molecular Formula: C24H22F3N5O5
Formula Weight: 517.46
CAS No.: 1188910-76-0
Description Review
Description

CEP-32496, also known as Agerafenib, RXDX-105, or RXDX105, is a small molecule inhibitor of the fibroblast growth factor receptor (FGFR) pathway. It is being investigated as a potential treatment for cancer, particularly solid tumors such as bladder cancer and lung cancer.

Chemical name: N-(4-{[5-(2-amino-4-pyridinyl)-2-thienyl]amino}quinazolin-6-yl)-2-propenamide

Molecular formula: C22H18N6O2S

Formula weight: 422.48 g/mol

CAS No: 1188910-76-0

Top 10 Keywords from Google:

  1. CEP-32496
  2. Agerafenib
  3. FGFR inhibitor
  4. Cancer treatment
  5. Solid tumors
  6. Bladder cancer
  7. Lung cancer
  8. Clinical trials
  9. Molecular targeted therapy
  10. Small molecule inhibitor

Synonyms: CEP-32496 is also known by the following synonyms:

  • Agerafenib
  • RXDX-105
  • RXDX105
  • N-(4-{[5-(2-amino-4-pyridinyl)-2-thienyl]amino}quinazolin-6-yl)-2-propenamide

Health Benefits of CEP-32496: As a potential cancer treatment, CEP-32496 could provide significant health benefits to patients with solid tumors such as bladder cancer and lung cancer. By inhibiting the FGFR pathway, this small molecule inhibitor could prevent the growth and spread of cancer cells, potentially leading to improved survival rates and quality of life for patients.

Potential Effects of CEP-32496: The main potential effect of CEP-32496 is its ability to inhibit the FGFR pathway, which is frequently dysregulated in cancer cells. This inhibition could prevent the growth and spread of cancer cells, potentially leading to tumor shrinkage and improved patient outcomes. Additionally, CEP-32496 has been shown to have synergistic effects when combined with other cancer treatments, such as chemotherapy and immunotherapy.

Product Mechanism: CEP-32496 works by inhibiting the FGFR pathway, a key signaling pathway involved in cell growth and survival. Inhibition of this pathway can prevent the growth and survival of cancer cells, potentially leading to tumor shrinkage and improved patient outcomes.

Safety: Like all cancer treatments, CEP-32496 has potential side effects that must be carefully monitored. However, clinical trials have indicated that this small molecule inhibitor is generally well-tolerated and has a manageable safety profile. Common side effects include fatigue, nausea, and diarrhea, while more serious side effects such as cardiovascular events and severe skin reactions are rare.

Side Effects: Common side effects of CEP-32496 include fatigue, nausea, and diarrhea. More serious side effects such as cardiovascular events and severe skin reactions are rare but possible. As with all cancer treatments, patients should be carefully monitored for side effects and any adverse reactions should be reported to their healthcare provider immediately.

Dosing Information: The optimal dosing of CEP-32496 may vary depending on the type and stage of cancer being treated, as well as other factors such as the patient's age, weight, and overall health. Dosages will typically be determined by the patient's healthcare provider and may be adjusted over time based on the patient's response to treatment.

Conclusion: CEP-32496 shows great promise as a potential treatment for solid tumors such as bladder cancer and lung cancer. By inhibiting the FGFR pathway, this small molecule inhibitor could prevent the growth and spread of cancer cells, potentially leading to improved survival rates and quality of life for patients. While there are potential side effects associated with this treatment, clinical trials have indicated that it is generally well-tolerated and has a manageable safety profile. As research into CEP-32496 continues, it is hoped that this promising cancer treatment will become widely available to patients in need

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us